{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:57:08Z","timestamp":1777701428658,"version":"3.51.4"},"reference-count":8,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Interferon &amp; Cytokine Research"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:p>\n                    Peginterferon alfa (alfa) increases the risk of autoimmune disease. Peginterferon lambda-1a (Lambda) acts through a receptor with a more liver-specific distribution compared to the alfa receptor. In a phase-2b study, 525 treatment-naive patients with chronic hepatitis C virus (HCV) infection received ribavirin and Lambda interferon (120, 180, or 240\u2009\u03bcg) or alfa interferon (180\u2009\u03bcg) for 24 (genotypes 2 and 3) or 48 (genotypes 1 and 4) weeks. Retrospective analysis found that adverse events of MedDRA-coded thyroid dysfunction and abnormal levels of thyroid-stimulating hormone (TSH) were significantly more frequent with alfa versus Lambda (12% versus 2.6% and 15.2% versus 3.4%, respectively, both\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt;0.0001). Most Lambda recipients with abnormal TSH had levels below the lower limit of normal; the frequency of low and high TSH was similar in alfa recipients with abnormal TSH. Blinded review by an endocrinologist found that new-onset primary hypothyroidism or painless thyroiditis was less frequent with Lambda versus alfa (0.5% and 1.8% versus 5.3% and 7.5%, respectively,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt;0.0001). Most TSH elevations reflected new-onset hypothyroidism requiring treatment, while most markedly suppressed TSH values reflected probable painless thyroiditis and resolved without sequelae. In conclusion, HCV-infected patients treated with Lambda\/ribavirin experienced fewer adverse events of thyroid dysfunction compared with patients treated with alfa\/ribavirin.\n                  <\/jats:p>","DOI":"10.1089\/jir.2014.0233","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T16:54:09Z","timestamp":1442422449000},"page":"841-843","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Peginterferon Lambda-1a Is Associated with a Low Incidence of Autoimmune Thyroid Disease in Chronic Hepatitis C"],"prefix":"10.1177","volume":"35","author":[{"given":"Paul","family":"Fredlund","sequence":"first","affiliation":[{"name":"Bristol-Myers Squibb"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Hillson","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Gray","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Shemanski","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dessislava","family":"Dimitrova","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subasree","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,11,1]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2011.07.002"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02239-12"},{"key":"e_1_3_3_4_1","unstructured":"Genentech USA September. 2014. Pegasys\u00ae (pegylated interferon alfa-2a). Prescribing Information Genentech Inc. USA [Internet]; September 2014."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.022"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055364"},{"issue":"4","key":"e_1_3_3_7_1","first-page":"994A","article-title":"Safety and efficacy of pegylated interferon lambda (lambda) compared to pegylated interferon \u03b1-2a (alfa-2a) in HCV-infected patients (G1\/2\/3) with compensated cirrhosis: EMERGE phase IIb efficacy and safety results through week 12","volume":"54","author":"Rodriguez-Torres M","year":"2011","unstructured":"Rodriguez-Torres M, , Hillson JL, , Bacon B, , Box T, , Hassanein T, , Greenbloom S, , Lawitz E, , Vargas H, , Vierling JM, , Horga A, et al. 2011. Safety and efficacy of pegylated interferon lambda (lambda) compared to pegylated interferon \u03b1-2a (alfa-2a) in HCV-infected patients (G1\/2\/3) with compensated cirrhosis: EMERGE phase IIb efficacy and safety results through week 12. Hepatology, 54 (4 suppl):994A\u2013995A.","journal-title":"Hepatology"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP12195.RA"},{"issue":"3","key":"e_1_3_3_9_1","first-page":"399","article-title":"The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C","volume":"89","author":"Watanabe U","year":"1994","unstructured":"Watanabe U, , Hashimoto E, , Hisamitsu T, , Obata H, , Hayashi N. 1994. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol, 89(3):399\u2013403.","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Interferon &amp; Cytokine Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jir.2014.0233","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jir.2014.0233","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jir.2014.0233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:33:13Z","timestamp":1777455193000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jir.2014.0233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":8,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1089\/jir.2014.0233"],"URL":"https:\/\/doi.org\/10.1089\/jir.2014.0233","relation":{},"ISSN":["1079-9907","1557-7465"],"issn-type":[{"value":"1079-9907","type":"print"},{"value":"1557-7465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}